Foghorn Therapeutics rises as FDA lifts clinical hold on cancer drug trial
05/06/2023 15:37
(Updates)
** Shares of biopharma company Foghorn Therapeutics Inc
FHTX.O surge 12% to $7.90, hitting a 4-month high
** Company says U.S. FDA on June 1 lifted clinical hold on
early-stage dose escalation study of blood cancer drug FHD-286
** Health regulator last year had placed a full clinical
hold on the trial, months after a partial hold due to one death
** FHTX plans to commence an early-stage study of FHD-286 in
combination with chemotherapy medications, decitabine or
cytarabine, to treat relapsed and/or refractory acute myeloid
leukemia (AML) patients in Q3 of 2023
** AML is a fast-growing cancer of blood cells that starts
in the bone marrow and can spread to other organs
** Including session's gains, FHTX stock up ~24% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))